The Thyroid Patient Advocacy-UK
(TPA-UK) Response to: “A Statement from the British Thyroid Association
Executive Committee on Armour® Thyroid”
TPA-UK disagrees with many of the statements made by the Executive Committee
of the British Thyroid Association (BTA) on natural desiccated porcine
thyroid extract (Armour® Thyroid, USP). TPA-UK are very concerned
that the BTA continue to advise that L-thyroxine (T4)-replacement remains
the treatment of choice despite the amount of evidence contrary to their
opinion, showing it to be ineffective in relieving many patients' symptoms.
This research paper extensively refutes the incorrect and inaccurate BTA
statements on Armour Thyroid.
Warning:
The BTA statements included in this paper deal with hypothyroidism as
deficient thyroid secretion only. It has no bearing on deficient post-thyroid
operations upon thyroid hormones.
The Thyroid Patient Advocacy
–UK (TPA-UK) response to the British Thyroid Association’s
(BTA) Statement on the Use of Combination Thyroxine/Triiodothyronine (Liothyronine)
Therapy
TPA-UK believes that the experience of patients is not being considered
in the diagnosis and treatment of hypothyroidism, and NHS doctors fail
to offer alternative therapy if L-thyroxine is ineffective in resolving
symptoms or is poorly tolerated by patients. Although ‘evidence
based medicine’ is to be applauded, much of the evidence base for
the treatment of hypothyroidism is based on research that does not consider
the patient’s experience and may be flawed. This research paper
refutes the BTA's incorrect and inaccurate statements regarding combination
T4/T3 therapy.
Warning:
The BTA statements included in this paper deal with hypothyroidism as
deficient thyroid secretion only. It has no bearing on deficient post-thyroid
operations upon thyroid hormones.